ArticleRespiratory research2019

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

M T Driessen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.